Link between gut dysbiosis and chronic diseases explored in new study

Study explores the ecological causes of gut dysbiosis and its link to human diseases, revealing how imbalances in gut microbiota composition, influenced by host-derived factors like oxygen and nitrate, contribute to various chronic conditions.

FILAMENT HEALTH ANNOUNCES HEALTH CANADA AUTHORIZATION FOR PHASE 2 CLINICAL TRIAL STUDYING BOTANICAL PSILOCYBIN FOR OPIOID USE DISORDER | Psychedelic Invest

Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE:7QS) (“Filament” or the “Company“), a clinical‐stage natural psychedelic drug development company, today announced Health Canada approval for a phase 2 clinical

October 10, 2023

Risk adjusted net present value: What is the current valuation of Vigil Neuroscience’s Iluzanebart?

Iluzanebart is a monoclonal antibody commercialized by Vigil Neuroscience, with a leading Phase III program in Neurodegenerative Diseases.

December 14, 2024

New research on long COVID prevalence and risk factors

Early in the pandemic, many people who had SARS-Cov-2 infection or COVID-19 began to report that they couldn’t shake off their symptoms even after a

June 18, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.